First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.
Wang ZX, Peng J, Liang X, Cheng Y, Deng Y, Chen K, Zhang M, Zhang J, Wang W, Cao B, Jin Y, Sun M, Lin Y, Luo S, Li Z, Yang L, Ke Y, Yu H, Li J, Wang Q, Zhu J, Wang F, Xu RH.
Wang ZX, et al.
Med. 2024 Jun 9:S2666-6340(24)00213-7. doi: 10.1016/j.medj.2024.05.009. Online ahead of print.
Med. 2024.
PMID: 38870931